Characteristics of Adult Patients With Melanoma Diagnosis <40 Years Age.

Study Purpose

The primary objective of the study is to analyse a local cohort of patients aged 18-39 years with melanoma diagnosis in order to determine the prevalence of the disease in this age group. Secondary objectives are the following:

- To identify risk factors associated with melanoma in young people.

- To characterise the phenotype and dermoscopic features of melanoma in patients aged 18-39 years.

- To analyse the relationship between the clinical and histopathological features of melanoma in young people.

- To identify the mutational status of B-RAF in the sample of patients analysed.

Recruitment Criteria

Accepts Healthy Volunteers Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms	No
Study Type An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes. An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes. Searching Both is inclusive of interventional and observational studies.	Observational [Patient Registry]
Eligible Ages	18 Years - 39 Years
Gender	All

More Inclusion & Exclusion Criteria

Inclusion Criteria:

1. written informed consent. 2. age > 18 years and < 40 years. 3. diagnosis of cutaneous melanoma even non-primary.

Exclusion Criteria:

Trial Details

Trial ID: This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.	NCT06994208
Phase Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans. Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data. Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.
Lead Sponsor The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.	Ente Ospedaliero Ospedali Galliera
Principal Investigator The person who is responsible for the scientific and technical direction of the entire clinical study.	Sanja Javor
Principal Investigator Affiliation	Ente Ospedaliero Ospedali Galliera
Agency Class Category of organization(s) involved as sponsor (and collaborator) supporting the trial.	Other
Overall Status	Not yet recruiting
Countries
Conditions The disease, disorder, syndrome, illness, or injury that is being studied.	Melanoma of Skin

Arms & Interventions

Arms

: ARM 1

Patients with melanoma diagnosis aged between 18 and 39 years.

Interventions

Contact Information

This trial has no sites locations listed at this time. If you are interested in learning more, you can contact the trial's primary contact:

Sanja Javor, MD

[email protected]

+390105634271

For additional contact information, you can also visit the trial on clinicaltrials.gov.

Clinical Trial Finder